Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Boehringer Ingelheim Stories

2014-03-21 08:24:55

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, March 21, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin, an...

2014-03-20 23:33:37

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that John Olszewski of Boehringer Ingelheim USA will speak at Pharmica’s SharePoint Conference for the Life Sciences Industry on June 4th and 5th in Plymouth Meeting, PA. Plymouth Meeting, PA (PRWEB) March 20, 2014 As part of its continued service to the industry, Pharmica will host its 10th SharePoint conference in Plymouth Meeting, PA on June 4-5, 2014. The two day conference will...

2014-03-19 23:31:58

According to a Court Order filed in March 13, new sanctions were imposed on Boehringer Ingelheim for Pradaxa Multidistrict Litigation discovery abuses. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) March 19, 2014 AttorneyOne.com, a recognized authority on law, updated the website recently and now,...

2014-03-13 23:26:43

Roger C. Denton, Plaintiffs' Co-Lead Counsel in the Pradaxa® MDL, provides an update on the Pradaxa® Multidistrict Litigation (MDL 2385), particularly that the first trial is now set to begin this fall. St. Louis, MO (PRWEB) March 13, 2014 The first trial in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385, Case No. 12-md-2385) is set to begin this fall in the United States District Court...

2014-03-11 23:30:43

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) March 11, 2014 The prescription drug safety center DrugNews.net is announcing new information on the site about the blood thinner Pradaxa. A new report shows the Food and Drug Administration of Jordan recently approved the popular drug, marking the 100th country to authorize its use*. DrugNews is a free...

2014-03-11 23:27:48

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Stephan Klaschka, Director, Global Innovation Strategy of Boehringer Ingelheim will be speaking at Pharmica’s “Pharma 3.0 – The Digital Medicine Era” conference to be held April 30th & May 1st, 2014 in Conshohocken, PA. Conshohocken, PA (PRWEB) March 11, 2014 The transition to a services and outcome focus is underway in healthcare. Digital medicine provides the...

2014-03-07 23:25:20

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Chicago, IL (PRWEB) March 07, 2014 The prescription drug safety center DrugRisk.com is announcing updated legal news on the site for patients taking the blood thinner Pradaxa. In a new report, lawsuits allege the research institute that conducted trails of Pradaxa for its FDA approval failed to disclose side effects like internal...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

2014-03-05 23:02:23

The Firm is evaluating Pradaxa lawsuits on behalf of patients who allegedly suffered serious and life-threatening internal bleeding due to Pradaxa. New York, New York (PRWEB) March 05, 2014 As thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) continue to move forward in federal court, Bernstein Liebhard LLP notes that newly unsealed court documents indicate that Boehringer Ingelheim did not inform federal regulators of a data analysis that indicated Pradaxa was...

2014-03-05 23:01:52

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company presenting Llaves para una mejor salud (Keys to a Healthier You) diabetes education pavilion. ACA and Medicaid health insurance pavilion providing one-to-one support. Phoenix, AZ (PRWEB) March 05, 2014 On Saturday, March 8, 2014, the National Alliance for Hispanic Health kicks off the 2014 ¡Vive tu vida! Get Up! Get Moving!® 10-event series in Phoenix, Arizona with local community-based organization partner,...